Fig. 2
Willingness-to-pay curve. The acceptability curve allows the identification of the likelihood of erenumab being cost-effective against topiramate (dark black dashes) and against placebo (grey dots) according to different willingness to pay. The probability of erenumab being cost-effective is above > 50% in the potential efficiency threshold ranges in Spain (30,000€ per QALY)